Cell therapy technology specialist TQ Therapeutics has acquired wholly owned subsidiary of Bristol Myers Squibb, Juno Therapeutics GmBH.
By purchasing all available shares of Juno Therapeutics' German subsidiary, TQ will have access to Juno's cell therapy expertise, which will assist the company in developing its cell processing platform.
TQ Therapeutics is currently focused on decentralising, scaling, automating and expediting the cell therapy development and production process through its platform.
By achieving this, the company hopes to make life-changing cell and gene therapies more accessible to patients worldwide.
Through the acquisition of Juno GmbH, TQ will gain access to the company's intellectual property and licensing agreements, which will assist the company in the further development of its cell processing platform.
“This acquisition presents an incredible opportunity for us to continue development of our breakthrough ultra-short extracorporeal cell and gene therapy approach to create treatments of the future,” said Dr. Christian Eckert, CEO of TQx.
“This strategic transaction reinforces our commitment to making cell and gene therapy broadly accessible to address the medical needs of many patients.”